Serum concentrations of interleukin-6 and tumor necrosis factor alpha in patients with spondyloarthritis: a relationship between systemic inflammation and anemia
https://doi.org/10.20538/1682-0363-2022-2-115-121
Abstract
Aim. To assess the relationship between the activity of systemic inflammation and the hemoglobin level in patients with spondyloarthritis (SpA).
Materials and methods. We examined 92 patients with SpA aged 42.9 ± 11.6 years (SpA duration – 14.8 ± 9.6 years, 55 (60%) men). We calculated the BASDAI and ASDAS-CRP scores, performed complete blood count, evaluated erythrocyte sedimentation rate (ESR), ferrokinetic parameters, C-reactive protein (CRP) level, and serum concentrations of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6).
Results. Anemia was found in 52 (57%) patients: 13 (25%) patients were diagnosed with anemia of inflammation (AI), 39 (75%) individuals had a combination of AI and iron deficiency anemia. A significant increase in CRP (17.8 vs. 9.0 mg / l, respectively; p = 0.001) and ESR (23 vs. 10 mm / h, p < 0.001), a tendency toward an increase in IL-6 levels (5.4 vs. 4.1 pg / ml, p = 0.051), and no difference in TNF-α levels (3.4 vs. 3.0 pg / ml, p = 0.245) were revealed in patients with anemia compared with patients with normal hemoglobin level. The hemoglobin concentration was negatively correlated with the CRP level (r = –0.327, p = 0.001) and ESR (r = –0.527, p < 0.001). IL-6 was positively correlated with the levels of TNF-a, CRP, and ESR (r = 0.431, r = 0.361, r = 0.369; all p < 0.001). With the IL-6 concentration >10 pg / ml, the odds for anemia were 5.3 times higher (95% confidence interval: 1.4–19.9, p = 0.009).
Conclusion. The relationship between the activity of systemic inflammation and anemia in patients with SpA was confirmed. Taking into account the pathogenesis of AI, the aim of antianemic treatment is to achieve remission or minimal activity of SpA. Additional studies are required to determine the effect of anti-inflammatory therapy on the development and course of anemia in patients with SpA.
About the Authors
К. N. SafarovaRussian Federation
112, Bolshaya Kazachia Str., Saratov, 410012
E. A. Fedotov
Russian Federation
27, Gvardeyskaya Str., Saratov, 410033
A. P. Rebrov
Russian Federation
112, Bolshaya Kazachia Str., Saratov, 410012
References
1. Kassebaum N.J., Jasrasaria R., Naghavi M., Wulf S.K., Johns N., Lozano R. et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624. DOI: 10.1182/blood-2013-06-508325.
2. Мартынов С.А., Шестакова М.В., Шилов Е.М., Шамхалова М.Ш., Викулова О.К., Сухарева О.Ю. и др. Распространенность анемии у больных сахарным диабетом 1 и 2 типа с поражением почек. Сахарный диабет. 2017;20(5):318– 328. DOI: 10.14341/DM9369.
3. Mentz R.J., Greene S.J., Ambrosy A.P., Vaduganathan M., Subacius H.P., Swedberg K. et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction. Circ. Hear Fail. 2014;7(3):401–8. DOI: 10.1161/CIRCHEARTFAILURE.113.000840.
4. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 2013;9(4):205–15. DOI: 10.1038/nrrheum.2012.183.
5. Рукавицын О.А. Анемия хронических заболеваний: отдельные аспекты патогенеза и пути коррекции. Онкогематология. 2016;11(1):37–46. DOI: 10.17650/1818-8346-2016-11-1-37-46.
6. Эрдес Ш.Ф., Ребров А.П., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В.и др. Спондилоартриты: современная терминология и определения. Терапевтический архив. 2019; 91 (5): 84–88. DOI: 10.26442/00403660.2019.05.000208.
7. Sieper J., Rudwaleit M., Baraliakos X., Brandt J., Braun J., Burgos-Vargas R. et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 2009;68:1–44. DOI: 10.1136/ard.2008.104018.
8. Muñoz M., Acheson A.G., Auerbach M., Besser M., Habler O., Kehlet H. et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233–247. DOI: 10.1111/anae.13773.
9. Bal A., Unlu E., Bahar G., Aydog E., Eksioglu E., Yorgancioglu R. Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clin. Rheumatol. 2006;26(2):211–215. DOI: 10.1007/s10067-006-0283-5.
10. Elkayam O., Yaron I., Shirazi I., Yaron M., Caspi D. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol. Int. 2000;19(3):101–105. DOI: 10.1007/s002960050111.
11. Sieper J., Porter-Brown B., Thompson L., Harari O., Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis . 2014;73(1):95– 100. DOI:10.1136/annrheumdis-2013-203559.
12. Sieper J., Braun J., Kay J., Badalamenti S., Radin A.R., Jiao L.et al. Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann. Rheum. Dis. 2015;74(6):1051– 1057. DOI: 10.1136/annrheumdis-2013-204963.
13. Favalli E.G. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol. Ther. 2020;7(3):473–516. DOI: 10.1007/s40744-020-00219-2.
14. Corrado A., Di Bello V., D’Onofrio F., Maruotti N., Cantatore F.P. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis. Int. J. Immunopathol. Pharmacol. 2017;30(3):302–307. DOI: 10.1177/0394632017714695.
15. Niccoli L., Nannini C., Cassarà E., Kaloudi O., Cantini F. Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring anti-TNFα drugs and therapy-induced changes. Int. J. Rheumю Dis. 2012;15(1):56–61. DOI: 10.1111/j.1756-185X.2011.01662.x.
16. Yan Y., Guo T.M., Zhu C. Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis. Biochem. Cell Biol. 2018;96(4):450–456. DOI:10.1139/bcb-2017-0267.
17. Сафарова К.Н., Дорогойкина К.Д., Ребров А.П. Является ли анемия клиническим маркером НПВП-индуцированного поражения верхних отделов желудочно-кишечного тракта у пациентов со спондилоартритами? Альманах клинической медицины. 2019;47(5):410–418. DOI: 10.18786/2072-0505-2019-47-037.
Review
For citations:
Safarova К.N., Fedotov E.A., Rebrov A.P. Serum concentrations of interleukin-6 and tumor necrosis factor alpha in patients with spondyloarthritis: a relationship between systemic inflammation and anemia. Bulletin of Siberian Medicine. 2022;21(2):115-121. https://doi.org/10.20538/1682-0363-2022-2-115-121